Your Reliable Partner for Cell-based N-Glycan Array

N-linked glycosylation is one of the post-translational modifications of proteins. Its amino acid characteristic sequence is Asn-X-Ser/Thr (X represents any amino acid except proline). All N-glycans contain two N-acetylglucosamine residues and three mannose residues formed together. CD BioGlyco has developed the Cell-based Glycan Display Array by the human embryonic kidney 293 (HEK293) cell line. The cell-based N-glycan array provides information about the biomolecular structure of positive and negative binding, effectively screening many types of glycans, proteins pathogens, etc. In addition, we offer a Cell-based O-Glycan Array, Cell-based Glycosaminoglycan (GAG) Array, and Cell-based Glycoprotein Array.

• Design and validation of cell-based N-glycan array

• Design
  We use HEK293 cells to construct cell-based N-glycan arrays in-solution displaying defined peripheral N-linked Glycan. Since the conserved core glycan structure is already expressed on the cell surface, the long-time synthesis required to construct complex carbohydrates is avoided. Our researchers use a small number of glycosyltransferases compatible with cell surface glycosylation to introduce sialic acid, L-fucose, and others into peripheral glycans on the cell surface to form cell arrays displaying multiple N-glycans.
• Validation
  For the constructed cell-based arrays, we identify whether N-glycans successfully bind to the cell surface by the following services. The binding specificity of cell-based arrays is measured by coupled lectins. The modified cell-based array is probing with nucleoside-binding proteins or antibodies.

• Screening for high-affinity ligands

With the Glycan Display Platform, we provide high throughput screening and high-affinity ligand identification services. Notably, high affinity and highly selective glycan ligands are effective therapeutic tools for antibody-based therapeutics. Conventional Glycan Microarrays are also suitable for the discovery of high-specific glycan ligands. Therefore, the cell-based N-glycan array is further evaluated by our research group.

Our analysts observe the composition of the cell clusters through a double-staining service. We provide high-throughput flow cytometry analysis services and fluorescence observation services. In addition, cell-based N-glycosylation is analyzed by chromatography and liquid chromatography-tandem mass spectrometry (LC-MS/MS). The mass-to-charge ratio (m/z) values corresponding to each spot corresponding to a single N-glycan are obtained by matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) in positive ion mode. The specific sensitivity of ligands is analyzed by immunohistochemistry and cell count normalization.

Fig.1 Schematic diagram of cell-based N-glycan array analysis. (CD BioGlyco)

Publication

Applications of Cell-based N-Glycan Array

• Cell-based N-glycan array for probing glycan-glycan-bound protein interactions.
• Cell-based N-glycan arrays are an effective chemical tool for immune protein recognition glycan recognition.
• Cell-based N-glycan arrays have made significant contributions to the discovery and identification of new GBP. Meanwhile, it plays a role in microbial recognition and invasion activities.
• Cell-based N-glycan arrays provide valuable information in immunological studies. It asks for details of known endogenous immune receptors for glycan binding or binding of neoepitopes found to carry the natural ligands.
• Cell-based N-glycan arrays support an in-depth biomarker analysis of glycans from the immune system.
• Furthermore, cell-based N-glycan arrays are novel targets for the study of circulating immune cells outside, circulating cancer cells, and tumor-infiltrating immune cells.

Advantages of Us

• The cell-based N-glycan array we provide simplifies the service flow, allowing the specific capture of immune cell subtypes from mixed populations, eliminating the need for negative or positive selection.
• Our optimized detection service is reproducible, sensitive, and versatile.
• Our research group overcomes the shortcomings of poor throughput, sample limitations, and narrow information to provide high-throughput screening services for cell-based N-glycan arrays.

CD BioGlyco attaches great importance to the needs of clients and the quality of service. Our company is committed to providing convenient and integrated services. If you are interested in our services, please feel free to contact us.